Washington State Medicaid Prescription Drug Purchasing: Preferred Drug List
|
|
- Gwendolyn Stevenson
- 6 years ago
- Views:
Transcription
1 Washington tate Medicaid Prescription rug Purchasing: Preferred rug List NLPE Conference eptember 21, 2011 John Bowden Joint Legislative udit & eview Committee
2 JLC Background he Joint Legislative udit and eview Committee (JLC): Consists of 8 senators and 8 representatives equally divided between emocrats and epublicans. eceives assignments through: Budget provisos; Policy bills; and opics selected by JLC members. Medicaid Prescription rug tudy eptember 21,
3 Why id JLC Conduct the Medicaid rug tudy? Y M N E In 2009, JLC directed staff to review Medicaid prescription drug expenditures because: In 2003, to save on prescription drug costs, the Legislature mandated H, Health Care uthority, and epartment of Labor and Industries to create a state preferred drug list for outpatient prescriptions. $46.5 million in Medicaid prescription drug cost savings were assumed in Operating Budget. However, $9.4 million was restored in 2004 upplemental Budget. No information on costs savings after eport Page 2 Medicaid Prescription rug tudy eptember 21,
4 udit Questions 1. Has H complied with statutory requirements in creating and using the state preferred drug list (PL)? 2. Has the PL resulted in Medicaid prescription drugs cost savings? 3. Is a separate process needed for estimating PL savings for budget development purposes? eport Page 2-3 Medicaid Prescription rug tudy eptember 21,
5 What is the Preferred rug List? P O G M B C K G O N preferred drug list (PL) is a list of prescription drugs selected to save money and ensure the safety, efficacy, and effectiveness of the drugs. he purpose of a PL is to guide practitioners in prescribing clinically appropriate, costeffective drugs. eport Page 1 Medicaid Prescription rug tudy eptember 21,
6 How Medical ssistance Prescription rug Purchasing Works Client Centers for Medicare & Medicaid ervices Practitioner prescribes drug. Client gets prescription filled at Pharmacy at no cost to Client CM maintains contract with Manufacturer for federally established unit rebate amounts Pharmacy Pharmacy purchases drugs from Wholesaler or from the Manufacturer Pharmacy submits claim to H. H reimburses Pharmacy for filled prescriptions + dispensing fee rug Manufacturer or Wholesaler H H invoices Manufacturer for rebates. Manufacturer sends rebates to H ource: JLC analysis of agency data. Medicaid Prescription rug tudy eptember 21,
7 First udit esult: Compliance tatute requires H to work with two other state agencies to: evelop a process that designates preferred drugs based on cost, safety, efficacy, and effectiveness; dopt rules governing practitioner endorsement and use of the PL; and Provide for reasonable exceptions to the PL. eport Page 2 & 9 Medicaid Prescription rug tudy eptember 21,
8 PL Process esignates Preferred rugs P O G M B C K G O N rug classes are groups of drugs which are used to treat specific diseases and conditions. he process compares the drugs within the drug classes to identify the drugs that are equally or more safe and effective, and when possible, less expensive. eport Page 5 Medicaid Prescription rug tudy eptember 21,
9 Preferred rug esignation Process Begins with rug Classes High overall expenditures High overall volume Large price variation among drugs rug classes reviewed for PL Medical reasons Low overall expenditures Low overall volume Little price variation among drugs rug classes not reviewed for PL eport Page 5 Medicaid Prescription rug tudy eptember 21,
10 Process for esignating Preferred rugs I E L Entity H taff Prescription rug Program (H, HC, and L&I) rug Effectiveness eview Project (W, 13 other states, and Canada) W Pharmacy and herapeutic (P&) Committee hird-party ctuary and Prescription rug Program (H, HC, and L&I) H, HC, and L&I irectors ctions eviews utilization data for drug classes with potential Medicaid savings. Nominates drug classes for review that have the greatest potential savings for the state as a whole. ubmits nominations to the rug Effectiveness eview Project (EP). elects drug classes, jointly with other EP members, to be reviewed or updated. Produces independent evidence-based reviews of the drug classes. eviews the evidence-based reports supplied by EP and makes recommendations about types of drugs for inclusion on the Washington PL. eview recommendations from the P& and conduct cost analysis to recommend preferred and non-preferred drugs. Make final decision about which drugs will be included on the preferred drug list. Emphasis of ction Cost Cost afety, Efficacy, and Effectiveness afety, Efficacy, and Effectiveness Cost, afety, Efficacy, and Effectiveness Cost, afety, Efficacy, and Effectiveness eport Page 6 Medicaid Prescription rug tudy eptember 21,
11 dopt ules Governing Practitioner Endorsement P O G M B C K G O N For the PL to work, practitioners should: Prescribe preferred drugs; or llow the substitution of preferred drugs for non-preferred drugs. Practitioners complete a short on-line form to become endorsing practitioners which allows automatic substitutions to occur. eport Page 7-8 Medicaid Prescription rug tudy eptember 21,
12 dopt ules Governing easonable Exceptions to the PL P O G M B C K G O N easonable exceptions are important because in certain instances, a preferred drug may not be clinically appropriate for a patient. If an endorsing practitioner wants a prescription automatically filled with a specific non-preferred drug, he or she can sign dispense as written on the prescription. eport Page 8 Medicaid Prescription rug tudy eptember 21,
13 Practitioners, Pharmacists, and se of the Preferred rug List Endorsing Practitioner Non-Endorsing Practitioner I E L eport Page 8 Medicaid Prescription rug tudy eptember 21,
14 econd udit esult: Cost avings everal factors complicate the ability to attribute or quantify specific cost savings to the PL ix positive indicators that the PL has produced Medicaid prescription drug cost savings Medicaid Prescription rug tudy eptember 21,
15 Factors that Complicate ttributing pecific Cost avings to the PL I E L PL not only cost containment effort concurrent efforts underway (e.g., reimbursement mechanisms and push to increase generic drug use) Market and population factors affecting costs (e.g., inflation, generics becoming available, new drugs, and population changes) Challenges with cost savings analysis methodologies (accuracy of all methodologies decreases over time) eport Pages Medicaid Prescription rug tudy eptember 21,
16 Percent Increase in verage aily Cost from FY 2003 to FY 2008 Positive Indicator #1: PL Cost Increases Less than Inflation and Non-PL rug Class Costs 35% I E L 30% 25% 20% 15% 10% 5% 0% PL rug Classes National rug Inflation Non-PL rug Classes ource: JLC analysis of H data and.. Bureau of Labor national drug inflation statistics. eport Pages Medicaid Prescription rug tudy eptember 21,
17 Positive Indicator #2: 28 PL rug Classes Capture lmost Half of Expenditures I E L PL drug classes accounted for 49 percent of Medicaid fee-for-service drug expenditures in FY his is because: he number of drug classes with preferred drugs increased from 7 in 2004 to 28 in Most of the higher expenditure drug classes have been included. eport Pages 15 Medicaid Prescription rug tudy eptember 21,
18 Prescription Claims (in millions) I E L Positive Indicator #3: More Prescriptions are Being Filled with Preferred rugs Note: based on current 28 PL classes. Preferred Non-preferred Fiscal Year eport Page 16 Medicaid Prescription rug tudy eptember 21,
19 Positive Indicator #4: se of ispense as Written has eclined I E L ispense as written (W) was used on about 50 percent of PL claims in In FY 2008, W was used on 5 percent of PL claims. ome practitioners have unusually high W prescribing patterns compared to their peers. In 2009, H was granted limited authority to impose restrictions on the W privileges of these practitioners. eport Pages Medicaid Prescription rug tudy eptember 21,
20 Positive Indicator #5: upplemental ebates from rug Manufacturers I E L H received supplemental rebates in 15 of the 28 drug classes. upplemental rebates increased each year since the PL was implemented. he state received $6.6 million in supplemental rebates in FY 2008 for drugs dispensed to Medicaid clients. eport Page 17 Medicaid Prescription rug tudy eptember 21,
21 Prescription Claims (in millions) Positive Indicator #6: se of Generic rugs has Increased I E L Generic Brand Fiscal Year eport Pages Medicaid Prescription rug tudy eptember 21,
22 hird udit esult: Budgeting I E L PL savings estimates are no longer necessary for budget development because: he PL is not a separate factor in forecasting drug expenditures savings from the PL are part of the base budget; and Increases in future savings are not likely to be large because: rug changes within drug classes are not usually significant; and emaining drug classes do not contain large expenditures or are excluded for medical reasons. eport Page 19 Medicaid Prescription rug tudy eptember 21,
23 udit esults ummary Has H complied with statutory requirements in creating and using the PL? Has use of the PL resulted in Medicaid prescription drug cost savings? However, specific PL cost savings cannot be calculated. Is a separate process for estimating savings still needed for budget development purposes? Yes Yes Not any more Medicaid Prescription rug tudy eptember 21,
24 Contact Information John Bowden Medicaid Prescription rug tudy eptember 21,
Pharmaceutical Management Medicaid 2019
Pharmaceutical Management Medicaid 2019 Toll-free Contact Number: (888) 327-0671 Pharmacy Administration: (810) 244-1660 Introduction Pharmaceutical Management promotes the use of the most clinically appropriate,
More informationAgency Report Item 11: Oregon Health Authority Meningitis Vaccination Program in Lane County
Agency Report Item 11: Oregon Health Authority Meningitis Vaccination Program in Lane County Analyst: Linda Ames Request: Acknowledge receipt of a report on the meningitis vaccination program in Lane County.
More informationBusiness Impact Analysis
ACTION: Final DATE: 05/23/2018 8:24 AM Business Impact Analysis Agency Name: Ohio Department of Medicaid (ODM) Regulation/Package Title: Dental services Rule Number(s): Rule 5160-5-01 with appendices A
More informationEvaluation of a Medicaid Psychotropic Drug Management Program in Utah
Evaluation of a Medicaid Psychotropic Drug Management Program in Utah Dominick Esposito James M. Verdier 2008 SAMHSA/CMS Invitational Conference on Medicaid and Mental Health Service/Substance Abuse Treatment
More informationPBMs: Impact on Cost and Quality of Pharmaceutical Care in the U.S.
Speaker Brian K. Solow, MD, FAAFP Optum Life Sciences Irvine, CA, USA PBMs: Impact on Cost and Quality of Pharmaceutical Care in the U.S. Brian K. Solow, MD, FAAFP Chief Medical Officer, Optum Life Sciences
More informationElectronic Prescription Service in England. Ian Lowry Programme Manager
Electronic Prescription Service in England Ian Lowry Programme Manager EPS a definition The Electronic Prescription Service will enable electronic prescriptions to be generated, transmitted, received and,
More informationProposed Amendment of 10A NCAC 26E.0603 Requirements for Transmission of Data
Proposed Amendment of 10A NCAC 26E.0603 Requirements for Transmission of Data Agency: Contact: DHHS/ Mental Health, Developmental Disabilities, and Substance Abuse Services Amanda Reeder, Rule-Making Coordinator
More informationHow Mail-Servi. Prepared for
How Mail-Servi ice Pharmacies Will Save $46.6 Billion Over the Next Decade and the Cost of Proposed Restrictions Prepared for February 2012 Table of Contents I. Executive Summary... 3 Major Findings on
More informationStrategies to Prevent Pharmaceutical Waste: Modifying Co-Pay Structures
Modifying Co-Pay Structures Extended producer responsibility (EPR) is a policy approach in which the producer s responsibility for their product extends to the post-consumer management of that product
More informationOVERVIEW OF WOMEN S HEALTH PROGRAMS
The women s health programs in Texas provide access to women s health, family planning, prenatal, and preventive care services to eligible women in need. In addition to improving health outcomes, the women
More informationPrescription Drugs North Carolina Policies. Carol Steckel, MPH Medicaid Director
Prescription Drugs North Carolina Policies Carol Steckel, MPH Medicaid Director March 19, 2013 Pharmacy Services Optional service provided each year to about 1.5 million beneficiaries by 2,200 pharmacy
More informationStatement Of. The National Association of Chain Drug Stores. For. U.S. Senate Committee on Finance. Hearing on:
Statement Of The National Association of Chain Drug Stores For U.S. Senate Committee on Finance Hearing on: 10:00 a.m. National Association of Chain Drug Stores (NACDS) 1776 Wilson Blvd., Suite 200 Arlington,
More informationREGULATORY IMPACT STATEMENT and COST-BENEFIT ANALYSIS (RISCBA)
State Budget Office Office of Regulatory Reinvention 111 S. Capitol Avenue; 8th Floor, Romney Building Lansing, MI 48933 Phone: (517) 335-8658 FAX: (517) 335-9512 REGULATORY IMPACT STATEMENT and COST-BENEFIT
More informationPharmaceutical System in the UK
Pharmaceutical System in the UK David Kullman Medicines, i Pharmacy and Industry Group Department of Health PPRI Conference, Vienna 30 September 2011 Disclaimer Conflict of interest: Nothing to disclose
More informationThe Changing Landscape of Opioids & Workers Compensation. Presented by: David Campbell, MA, CRC State of Michigan Workers Compensation Agency
The Changing Landscape of Opioids & Workers Compensation Presented by: David Campbell, MA, CRC State of Michigan Workers Compensation Agency 1 The Changing Landscape of Opioids & Workers Compensation is
More informationOHIO LEGISLATIVE SERVICE COMMISSION
OHIO LEGISLATIVE SERVICE COMMISSION Joseph Rogers and other LSC staff Fiscal Note & Local Impact Statement Bill: H.B. 117 of the 132nd G.A. Sponsor: Reps. Huffman and Brenner Status: As Introduced Local
More informationMedication trends shaping workers compensation. A 2018 update of the prevailing industry influences impacting pharmacy outcomes
Medication trends shaping workers compensation A 2018 update of the prevailing industry influences impacting pharmacy outcomes This page intentionally left blank Trends impacting workers compensation pharmacy
More informationIn its written comments on our draft report, CMS concurred with our recommendation.
Page 2 Kerry Weems We recommend that Congress and CMS consider the results our review, including the data provided, in any deliberations regarding Medicare Part D reimbursement. In its written comments
More informationInfant Formula Rebates
WIC Food Package Costs and Rebates Summary: Fiscal Year 2005 Page 1 WIC FOOD PACKAGE COSTS AND REBATES SUMMARY: FISCAL YEAR 2005 Office of Analysis, Nutrition, and Evaluation September 2007 WIC provides
More informationWA PMP Access by Public Payers. PDMP North Regional Meeting St. Louis, MO April 23-24
WA PMP Access by Public Payers PDMP North Regional Meeting St. Louis, MO April 23-24 Public Insurer Access PDMP Statute: Allows PDMP data to be provided to Medicaid and Workers Compensation Primary Goal:
More informationPHARMACY COMPLIANCE RISK AREAS FOR 2014
PHARMACY COMPLIANCE RISK AREAS FOR 2014 2014 San Juan Puerto Rico Regional Compliance Conference Darrell W. Contreras, Esq., LHRM, CHC-F, CHPC, CHRC 5 Risk Areas 1. Overbilling of Herceptin 2. Quality
More informationWebinar Series: Diabetes Epidemic & Action Report (DEAR) for Washington State - How We Are Doing and How We Can Improve.
Webinar Series: Diabetes Epidemic & Action Report (DEAR) for Washington State - How We Are Doing and How We Can Improve April 22, 2015 Qualis Health A leading national population health management organization
More informationSpring Understanding the potential of generic substitution
Spring 2014 Understanding the potential of generic substitution Understanding the potential of generic substitution Generic pricing reforms and the availability of generics for blockbuster drugs coming
More informationDepartment of Legislative Services
Department of Legislative Services Maryland General Assembly 2007 Session SB 105 FISCAL AND POLICY NOTE Revised Senate Bill 105 (The President, et al.) (By Request Administration) Education, Health, and
More informationStatement Of. The National Association of Chain Drug Stores. For. U.S. House of Representatives Committee on the Budget.
Statement Of The National Association of Chain Drug Stores For U.S. House of Representatives Committee on the Budget Hearing on: 2:00 p.m. 210 Cannon House Office Building National Association of Chain
More informationSummary of Related Documentation Pennsylvania House Bill 1846 of 2014
Summary of Related Documentation Pennsylvania House Bill 1846 of 2014 15 November 2018 Department of Labor & Industry BWC-Administrative Division 1171 S. Cameron St. Harrisburg PA 17104-2501 Essential
More informationNCPA LTC Division Newsletter
March 2016 NCPA LTC Division Newsletter NCPA Offers FDA Additional Information on Repackaging Draft Guidance NCPA recently joined with the American Society of Consultant Pharmacists (ASCP) in a follow
More informationLIPITOR AND YOU HELPFUL INFORMATION FOR UNDERSTANDING CHOLESTEROL AND RISKS
LIPITOR AND YOU HELPFUL INFORMATION FOR UNDERSTANDING CHOLESTEROL AND RISKS Learn what your cholesterol levels actually mean, and how you may save money on your prescription each month with the LIPITOR
More informationPharmaceutical Pricing & Reimbursement Information. PPRI Project Co-ordination Sabine Vogler, Gesundheit Österreich GmbH
PPRI - Comparative Analysis PPRI Project Co-ordination Sabine Vogler, Gesundheit Österreich GmbH PPRI Conference Vienna, 29 June 2007 PPRI Conference, Vienna, 29 June 2007 1 Comparative Analysis - Outline
More informationDepartment of Legislative Services Maryland General Assembly 2010 Session
Department of Legislative Services Maryland General Assembly 2010 Session SB 27 Senate Bill 27 Finance FISCAL AND POLICY NOTE Revised (Senator Conway) Health and Government Operations Health Insurance
More informationLegislative & Regulatory Update Brad Young, RxPlus Government Affairs
Legislative & Regulatory Update 2018 Brad Young, RxPlus Government Affairs Disclosures Brad Young reports no actual or potential conflicts of interest associated with this presentation. 2 Learning Objectives
More informationVaccine Starter Kit Program FAQs
Vaccine Starter Kit Program FAQs Program How does this program help Health Mart pharmacies provide vaccines for their customers? McKesson has designed a comprehensive program specifically for Health Mart
More informationFlorida MEDS-AD Waiver
Florida MEDS-AD Waiver Quarterly Progress Report January 1, 2014 March 31, 2014 1115 Research and Demonstration Waiver #11-W-00205/4 This page intentionally left blank Table of Contents This page intentionally
More informationOffice of the Auditor General Portage Avenue Winnipeg, Manitoba R3C 0C4
Office of the Auditor General 500-330 Portage Avenue Winnipeg, Manitoba R3C 0C4 April 2006 The Honourable George Hickes Speaker of the House Room 244, Legislative Building Winnipeg, Manitoba R3C 0V8 Dear
More informationDental Care for Children Subcommittee Meeting 9/23/14
Dental Care for Children Subcommittee Meeting 9/23/14 AHCA Leads Erica Floyd-Thomas Pam Hull Subcommittee Members Present Dr. Edward Zapert Department of Health Tami Miller Florida Dental Hygiene Association
More informationAn Evaluation Of Oregon s Evidence-Based Practitioner- Managed Prescription Drug Plan
Oregon s Drug Plan An Evaluation Of Oregon s Evidence-Based Practitioner- Managed Prescription Drug Plan Oregon s effort to manage drug usage helped curb spending, but health outcomes for patients have
More informationSUPPLEMENTAL NOTE ON HOUSE BILL NO. 2217
SESSION OF 2017 SUPPLEMENTAL NOTE ON HOUSE BILL NO. 2217 As Amended by House Committee on Health and Human Services Brief* HB 2217, as amended, would enact new law and amend the Kansas Pharmacy Act (Act)
More informationLAWS OF ALASKA AN ACT
LAWS OF ALASKA 01 Source HCS SB (RLS) am H Chapter No. AN ACT Requiring insurance coverage for autism spectrum disorders, describing the method for establishing a covered treatment plan for those disorders,
More informationSTATE & FEDERAL EFFORTS TO COMBAT THE OPIOID EPIDEMIC & IMPACT ON COMPLIANCE PROGRAMS GRACE E. REBLING OSBORN MALEDON P.A.
STATE & FEDERAL EFFORTS TO COMBAT THE OPIOID EPIDEMIC & IMPACT ON COMPLIANCE PROGRAMS GRACE E. REBLING OSBORN MALEDON P.A. Arizona Corporate Counsel Presentation May 8, 2018 Agenda 1. Overview of the Opioid
More informationAmendment 72 Increase Cigarette and Tobacco Taxes
Amendment 72 Increase Cigarette and Tobacco Taxes ANALYSIS Amendment 72 proposes amending the Colorado Constitution to: increase the state tax on a pack of cigarettes from $0.84 to $2.59; increase the
More informationPrescription Drug Importation: Can it Help America's Seniors? Safety of Imported Medications: I-SaveRx Case Study
Prescription Drug Importation: Can it Help America's Seniors? Safety of Imported Medications: I-SaveRx Case Study Presented By: Scott McKibbin Special Advocate For Prescription Drugs State Of Illinois
More informationAnalysis Item 13: Oregon Health Authority Meningitis Vaccination Program
Analysis Item 13: Oregon Health Authority Meningitis Vaccination Program Analyst: Linda Ames Request: Acknowledge receipt of a report on the meningitis vaccination program in Lane County. Recommendation:
More informationMArch The 2014 Drug Trend Report Highlights
MArch 2015 The 2014 Drug Report Highlights Highest Increase in U.S. Drug Spend Over Past Decade In 2014, the pharmacy landscape underwent a seismic change, and the budgetary impact to healthcare payers
More informationStatewide Substance Abuse Services
Statewide Substance Abuse Services Overview and Funding PRESENTED TO HOUSE SELECT COMMITTEE ON OPIOIDS AND SUBSTANCE ABUSE LEGISLATIVE BUDGET BOARD STAFF MARCH 2018 Presentation Overview Content of Presentation:
More informationInnovative Ways to Fund Harm Reduction Services New Mexico
Innovative Ways to Fund Harm Reduction Services New Mexico Laine M. Snow, MSW HIV Service Program Manager New Mexico Department of Health History and Importance of Harm Reduction New Mexico Sero-prevalence
More informationMedicaid Cost Containment and Potential Effects on Diabetic Beneficiaries
Medicaid Cost Containment and Potential Effects on Diabetic Beneficiaries White Paper October 2003 2003 The Health Strategies Consultancy LLC and Duke University, The Fuqua School of Business For more
More informationMarket Distortions from the 340B Drug Pricing Program
Market Distortions from the 340B Drug Pricing Program Adam J. Fein, Ph.D. www.drugchannels.net @DrugChannels The opinions and views expressed in this presentation are those of the author and may not reflect
More informationa guide to Reimbursement of Intermittent Catheters Know your options M2116N 04.08
a guide to Reimbursement of Intermittent Catheters 1 Know your options Coloplast Corp. Minneapolis, MN 55411 1.800.533.0464 usmedweb@coloplast.com www.us.coloplast.com is a registered trademark of Coloplast
More informationDepartment of Legislative Services Maryland General Assembly 2007 Session. FISCAL AND POLICY NOTE Revised
House Bill 785 Economic Matters Department of Legislative Services Maryland General Assembly 2007 Session FISCAL AND POLICY NOTE Revised (Delegate Malone, et al.) HB 785 Finance Cigarette Fire Safety Performance
More informationPhysician Injectable Drug List (PIDL) Department for Medicaid Services, HP, and Magellan Rx Management June 1, 2010
Physician Injectable Drug List (PIDL) Department for Medicaid Services, HP, and Magellan Rx Management June 1, 2010 Physician-Administered Drugs Physician-administered drugs are drugs, other than vaccines,
More informationPractice Advisory on Drug Coverage Parity across Medical and Pharmacy Benefits
Practice Advisory on Drug Coverage Parity across Medical and Pharmacy Benefits Introduction Oncology medications have historically been administered intravenously in a physician s office, infusion center
More informationAnesthesia Reimbursement
This drafted policy is open for a two-week public comment period. This box is not part of the drafted policy language itself, and is intended for use only during the comment period as a means to provide
More informationPharmaceutical reimbursement in Sweden Balancing benefits and costs. Andreas Engström Health Economist Dental and Pharmaceutical Benefits Agency
Pharmaceutical reimbursement in Sweden Balancing benefits and costs Andreas Engström Health Economist Dental and Pharmaceutical Benefits Agency 1 Agenda Background - Healthcare in Sweden - Pharmaceutical
More informationMaryland Department of Health and Mental Hygiene /Office of Systems, Operations and Pharmacy. Date Prescription will Start Denying at the
Maryland Medicaid Pharmacy Program & News ViewsNovember 2013 Maryland Department of Health and Mental Hygiene /Office of Systems, Operations and Pharmacy The Antipsychotic Peer Review Program is Expanding!
More informationMedicaid Reimbursement for Tobacco Cessation Quitline Activities
Medicaid Reimbursement for Tobacco Cessation Quitline Activities Sharon Brown Financial Management Group (FMG) Center for Medicaid, CHIP and Survey & Certification (CMCS) 1 CMS issued a State Medicaid
More informationWhat s New. Don t Forget! There are 2 different influenza vaccines available. Flu Vaccine. Michigan Newsletter Fall 2009
What s New Michigan Newsletter Fall 2009 Flu Vaccine Don t Forget! There are 2 different influenza vaccines available this year (one for seasonal flu and one for Novel H1N1 or swine flu). Both vaccines
More informationCARD/MAIL/PRE-APPROVAL/PREFERRED RIDER FOR PRESCRIPTION DRUG [INSURANCE] [Policy]holder: Group Policy No: Effective Date:
RIDER FOR PRESCRIPTION DRUG [INSURANCE] [Policy]holder: Group Policy No: Effective Date: CARD/MAIL/PRE-APPROVAL/PREFERRED The Prescription Drug Coverage under this Rider [replaces] [supplements] the Prescription
More informationMichigan Legislative and Regulatory Pharmacy Initiatives Update
Michigan Legislative and Regulatory Pharmacy Initiatives Update Michigan Association of Health Plans Summer Conference Carrie Germain, R.Ph. Health Alliance Plan Senior Director, Pharmacy, Quality and
More informationLegislative Bill Watch As of Thursday March, 13, 2014
Passed Bills Legislative Bill Watch As of Thursday March, 13, 2014 Bill Number and Title Bill Sponsors Summary Status HB 11 Overdose Reporting HB 23 Suicide Prevention Revisions H.B. 38 Second Substitute
More informationChapter 15 Section 1
Chapter 15 Section 1 Issue Date: November 6, 2007 Authority: 32 CFR 199.14(a)(3) and (a)(6)(ii) 1.0 APPLICABILITY This policy is mandatory for the reimbursement of services provided either by network or
More information32 CFR (a)(4), (a)(6)(iii), and (a)(6)(iv)
CHAPTER 15 SECTION 1 ISSUE DATE: November 6, 2007 AUTHORITY: 32 CFR 199.14(a)(4), (a)(6)(iii), and (a)(6)(iv) I. APPLICABILITY This policy is mandatory for the reimbursement of services provided either
More informationGeneral Providers. Tamper-Resistant Prescription Requirements
September 2008 Provider Bulletin Number 8138 General Providers Tamper-Resistant Prescription Requirements Effective with processing dates on and after October 1, 2008, written prescriptions for Kansas
More informationDIRECT REIMBURSEMENT
DIRECT REIMBURSEMENT DIRECT REIMBURSEMENT The ADA recognizes that the direct reimbursement concept can be an efficient, economical and cost-effective method of reimbursing the patient for dental expenses.
More informationPharmacy Audit Recovery Guidelines
1/1E DAW 1 DAW 1 Error The prescription order does not indicate the prescriber ordered brand name. 2 /2E DAW 2 DAW 2 Not Documented The documentation does not specify the patient s request for brand. Pharmacy
More information2015 Survey on Prescription Drugs
2015 Survey on Prescription Drugs AARP Research January 26, 2016 (For media inquiries, contact Gregory Phillips at 202-434-2544 or gphillips@aarp.org) https://doi.org/10.26419/res.00122.001 Objectives
More information2017 Drug Trends Series
2017 Drug Trends Series Part 1 Evaluating the traditional view Retail and mail-order prescriptions Published April 2018 1 2017 Drug Trends Series Traditional View First Script A year of important progress
More informationTherapeutics Initiative A SHORT HISTORY
Therapeutics Initiative A SHORT HISTORY Therapeutics Initiative, 1994 (10 individuals) Mission: To provide physicians and pharmacists with up-to-date, evidence-based, practical information on prescription
More informationFor more information, please contact your Molina Healthcare of New Mexico, Inc. Provider Service Representative toll free at (800)
December 2012 Dear Practitioner/Provider, Effective January 1, 2013, there will be major changes to CPT-4 codes for behavioral health nationwide. These changes impact all practitioner/provider types (e.g.,
More informationPHARMACEUTICALS: Their Role in the Cost of Health Care
PHARMACEUTICALS: Their Role in the Cost of Health Care Pennsylvania Health Care Cost Containment Council 225 Market Street, Suite 400 Harrisburg, PA 17101 Phone: (717) 232-6787 Fax: (717) 232-3821 http://www.phc4.org
More informationStrengthening our global leadership in treatment of addiction. Morgan Stanley Global Healthcare Conference September 13 th and 14 th 2018
Strengthening our global leadership in treatment of addiction Morgan Stanley Global Healthcare Conference September 13 th and 14 th 2018 Forward Looking Statements This presentation contains certain statements
More informationFlorida MEDS-AD Waiver
Florida MEDS-AD Waiver 2 nd Quarter Report April 1, 2015 June 30, 2015 Demonstration Year 10 1115 Research and Demonstration Waiver #11-W-00205/4 This page intentionally left blank Table of Contents I.
More informationDrug Use Indicators. Dr Olayinka Ogunleye Consultant Physician/Clinical Pharmacologist Department of Medicine, LASUTH, Ikeja, LAGOS
Drug Use Indicators Dr Olayinka Ogunleye Consultant Physician/Clinical Pharmacologist Department of Medicine, LASUTH, Ikeja, LAGOS 1 Background WHO (1995) Conference on Rational Use of Drugs in Nairobi
More informationJanuary 16, Dear Administrator Verma:
Ms. Seema Verma Administrator Centers for Medicare and Medicaid Services Department of Health and Human Services Attention: CMMI New Direction P.O. Box 8011 Baltimore, MD 21244-1850 Re: (CMS-4182-P) Medicare
More informationMassachusetts Medicaid pediatric high-risk asthma bundled payment pilot
University of Massachusetts Medical School escholarship@umms Commonwealth Medicine Publications Commonwealth Medicine 9-28-2011 Massachusetts Medicaid pediatric high-risk asthma bundled payment pilot Katharine
More information11/12/2015 THE LATEST ON THE 340B FRONT AGENDA MEGA GUIDANCE RELEASED. Mega Guidance released. Audit update from HRSA. Maintaining compliance
November 19, 2015 Connie Ouellette, Principal Carole Barker, Senior Consultant THE LATEST ON THE 340B FRONT berrydunn.com AGENDA Mega Guidance released Audit update from HRSA Maintaining compliance Areas
More informationAnthem Extras Packages for Seniors
Anthem Extras Packages for Seniors Talking Points and Frequently Asked Questions FOR VIRGINIA Background Anthem is proud to announce the availability of Anthem Extras Packages for Seniors, providing coverage
More informationMaine s New Opioid Prescribing Law & the Opioid Crisis: Implications for Providers
Maine s New Opioid Prescribing Law & the Opioid Crisis: Implications for Providers Gordon H. Smith, Esq., Executive Vice President Maine Medical Association May 3, 2016 Facing the Opioid Crisis Today Opioid
More informationChallenges for U.S. Attorneys Offices (USAO) in Opioid Cases
Challenges for U.S. Attorneys Offices (USAO) in Opioid Cases Overview On August 2, 2017, U.S. Attorney General Jeff Sessions announced a pilot program whereby a new federal data analysis program is being
More informationJuly 30, VIA TO
July 30, 2012 VIA EMAIL TO DMEPOS@cms.hhs.gov Elliot Klein Centers for Medicare and Medicaid Services 7500 Security Boulevard Mail Stop C5-03-17 Baltimore, MD 21244-1850 RE: Inherent Reasonableness of
More informationFY 2004 STATE BUDGET ADDICTION PREVENTION AND TREATMENT SUMMARY ANTICIPATED RESOURCES FOR THE FISCAL YEAR GENERAL FUND
No.12 2003 1675 Whitehorse-Mercerville Road, Hamilton, NJ 08619 Tel.: 609/689-0121 l FAX 609/689-3244 POLICY REPORT FY 2004 STATE BUDGET ADDICTION PREVENTION AND TREATMENT SUMMARY Governor James McGreevey
More informationTHE LATEST ON THE 340B FRONT
September 1, 2015 Connie Ouellette, Principal Carole Barker, Senior Consultant THE LATEST ON THE 340B FRONT berrydunn.com AGENDA Mega Guidance released! Audit update from HRSA Maintaining compliance Areas
More informationPREPARED BY THE CENTER FOR MEDICARE ADVOCACY, INC.
MEDICARE DRUG CARDS PROVE INCONSISTENT AND PROVIDE FEW DISCOUNTS FOR MEDICARE BENEFICIARIES TRYING TO REDUCE THE COST OF THE TEN MOST POPULAR BRAND-NAME DRUGS USED BY SENIORS PREPARED BY THE CENTER FOR
More informationSURVEY ABOUT YOUR PRESCRIPTION CHOICES
Editor s Note: This online data supplement contains supplemental material that was not included with the published article by William Shrank and colleagues, Patients' Perceptions of Generic Medications,
More informationCommunity Partnerships Division. Monitoring Visit Administrative Review Results for Ryan White Part A Provider
Community Partnerships Division Monitoring Visit Administrative Review Results for Updated February 214 Community Partnerships Division Administrative Review Report Sections and Assigned Reviewer Tabs:
More informationE-Prescribing, EPCS & PDMP: An Update
E-Prescribing, EPCS & PDMP: An Update Melissa A. Kotrys, MPH Chief Executive Officer July 27, 2018 Arizona Health-e Connection is now Health Current Arizona s primary resource for health information technology
More informationMedicare Part D Overutilization Monitoring System
Medicare Part D Overutilization Monitoring System Lisa Thorpe, Division of Part D Policy Gary Wirth, Division of Clinical and Operational Performance Medicare Drug Benefit and C&D Data Group July 17, 2013
More informationIndependent Assurance Statement by Bureau Veritas
Nestlé S.A. Independent Assurance of Compliance with the Nestlé Policy and Instructions for Implementation of the WHO International Code of Marketing of Breastmilk Substitutes in Kenya (May 2014) Independent
More informationRe: Implementation of the Federal Tamper-Resistant Prescription Pad Mandate
January 2, 2008 Ms. Carol Herrmann-Steckel Commissioner Alabama Medicaid Agency PO Box 5624 501 Dexter Avenue Montgomery, AL 36103-5624 Re: Implementation of the Federal Tamper-Resistant Prescription Pad
More informationPREFACE. Saskatchewan is participating in the Common Drug Review (CDR).
PREFACE OBJECTIVES The Drug Plan has been established to: provide coverage to Saskatchewan residents for quality pharmaceutical products of proven therapeutic effectiveness; reduce the direct cost of prescription
More informationReport to the Social Services Appropriations Subcommittee
Report to the Social Services Appropriations Subcommittee Medicaid Coverage and Reimbursement for Outpatient Physical Therapy and Outpatient Occupational Therapy Prepared by the Division of Medicaid and
More informationOutpatient Therapy Services
Payment Policy: Outpatient Therapy Services Purpose: Commonwealth Care Alliance (CCA) reimburses contracted providers for medically necessary covered outpatient therapy s. Therapy s may include physical
More informationAccess to Dental Services in. Reimbursement Rates and Administrative Streamlining
Access to Dental Services in Medicaid: The Effect of Reimbursement Rates and Administrative Streamlining Shelly Gehshan, M.P.P., and Andrew Snyder, M.P.A. National Academy for State Health Policy March
More informationQuestions and Answers on 2009 H1N1 Vaccine Financing
Questions and Answers on 2009 H1N1 Vaccine Financing General Financing Questions Considerations of financing distinguish between those related to the vaccine itself, the ancillary supplies needed to administer
More informationAddiction and Recovery Treatment Services (ARTS) Reimbursement Structure
Page 1 of 13 Billing Code Service Name Service Description ASAM Level APPROVED CODES & RATES APPROVED BY CENTERS FOR MEDICARE AND MEDICAID SERVICES AUGUST 25, 2017 Community Based Care Unit Lengths Annual
More informationTexas Vendor Drug Program Specialty Drug List Process. February 2019
Texas Vendor Drug Program Specialty Drug List Process February 2019 Table of Contents Table of Contents...1 1 About the Specialty Drug List...2 1.1 Information for Pharmacies... 2 1.2 Information for Managed
More informationReport. Uganda Pharmaceutical Sector Scan JUNE 2010
Report On the Uganda Pharmaceutical Sector Scan Part of Component 1 of MeTA Baseline Assessments JUNE 2010 Drafted by consultants: 1. Samuel Balyejjusa, B.Pharm., MPH 2. Paschal Mujasi, B.Pharm., MBA 3.
More informationThe Society welcomes the opportunity to respond the Department of Health s consultation on generic substitution.
Lindsey Gilpin Chairman of the English Pharmacy Board Telephone: 020 7572 2519 Fax: 0207 572 2501 e-mail: howard.duff@rpsgb.org 25 th March 2010 Dear Sir/Madam, Consultation on the proposals to implement
More informationChanges to Australian Government Hearing Services Program and Voucher scheme
Changes to Australian Government Hearing Services Program and Voucher scheme The Commonwealth Department of Health has published a report on its investigation into the future of the Hearing Services Program,
More information